Literature DB >> 32942974

Mir-320b Inhibits Pancreatic Cancer Cell Proliferation by Targeting FOXM1.

Zhou Jingyang1, Che Jinhui2, Xu Lu2, Yang Weizhong2, Li Yunjiu2, Wang Haihong2, Zhou Wuyuan2.   

Abstract

BACKGROUND: Pancreatic Ductal Adenocarcinoma (PDAC) is the most common and deadly cancer. Surgical resection is the only possible cure for pancreatic cancer but often has a poor prognosis, and the role of adjuvant therapy is urgently explored.
METHODS: MicroRNAs (miRNAs) play a very important role in tumorigenesis by regulating the target genes. In this study, we identified miR-320b lower-expressed in human pancreatic cancer tissues but relatively higher-expressed in the adjacent non-tumor tissues.
RESULTS: Consistently, the expression of miR-320b in different pancreatic cancer cell lines was significantly lower than the normal pancreatic cells. In order to identify the effects of miR-320b on cell growth, we overexpressed miR-320b in PANC-1 and FG pancreatic cancer cell lines, CCK8 and BrdU incorporation assay results showed that miR-320b inhibited cell proliferation. DISCUSSION: We next predicted miR-320b targeted FOXM1 (Forkhead box protein M1) and identified the negative relationship between miR-320b and FOXM1. We also demonstrated that elevated miR- 320b expression inhibited tumor growth in vivo.
CONCLUSION: All of these results showed that miR-320b suppressed pancreatic cancer cell proliferation by targeting FOXM1, which might provide a new diagnostic marker for pancreatic cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  FOXM1; MiR-320b; Pancreatic Ductal Adenocarcinoma (PDAC); cell proliferation; diagnostic marker; tumor growth

Mesh:

Substances:

Year:  2021        PMID: 32942974     DOI: 10.2174/1389201021999200917144704

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  6 in total

1.  Integrated Analysis of ECT2 and COL17A1 as Potential Biomarkers for Pancreatic Cancer.

Authors:  Wen-Liang Huang; Shu-Fen Wu; Xiao Huang; Shan Zhou
Journal:  Dis Markers       Date:  2022-06-08       Impact factor: 3.464

2.  Circ-FOXM1 promotes the proliferation, migration and EMT process of osteosarcoma cells through FOXM1-mediated Wnt pathway activation.

Authors:  Hao Zhang; Qiongqiong Zhou; Weimin Shen
Journal:  J Orthop Surg Res       Date:  2022-07-07       Impact factor: 2.677

3.  LncRNA NR2F2-AS1 functions as a tumor suppressor in gastric cancer through targeting miR-320b/PDCD4 pathway.

Authors:  Ming Luo; Shuangya Deng; Tong Han; Yanglu Ou; Yongjun Hu
Journal:  Histol Histopathol       Date:  2022-01-20       Impact factor: 2.130

4.  Up-Regulation of circEIF6 Contributes to Pancreatic Cancer Development Through Targeting miR-557/SLC7A11/PI3K/AKT Signaling.

Authors:  Tiequan Zhang; Mi Li; Haofeng Lu; Tao Peng
Journal:  Cancer Manag Res       Date:  2021-01-12       Impact factor: 3.989

Review 5.  MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review.

Authors:  Pamela Czajka; Alex Fitas; Daniel Jakubik; Ceren Eyileten; Aleksandra Gasecka; Zofia Wicik; Jolanta M Siller-Matula; Krzysztof J Filipiak; Marek Postula
Journal:  Front Physiol       Date:  2021-04-15       Impact factor: 4.566

6.  Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis.

Authors:  Jian Cheng; Yanghui Lou; Kai Jiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.